03.14.07
CytoDyn, Inc. has selected the Waisman Clinical BioManufacturing Facility (WCBF) at the University of Wisconsin at Madison to manufacture its DNA-based pre-flu vaccine. The pre-flu vaccine provides an alternative approach to immunization that could enhance the efficacy of flu vaccines for seasonal flu and bird flu. It uses DNA technology to implant a false memory of previous exposure to the flu virus, including the inactivated virus contained in standard vaccines. The company hopes to have clinical trials underway before the end of next year's flu season, according to Allen D. Allen, chief executive officer of CytoDyn.
The WCBF is designed to manufacture clinical-grade biological pharmaceuticals for Phase I and II trials. WCBF also has facilities for processing cell therapeutics, aseptic filling of parenteral therapeutics, and for producing recombinant proteins expressed in bacterial or mammalian systems.
The WCBF is designed to manufacture clinical-grade biological pharmaceuticals for Phase I and II trials. WCBF also has facilities for processing cell therapeutics, aseptic filling of parenteral therapeutics, and for producing recombinant proteins expressed in bacterial or mammalian systems.